skip to main content

Obstructive Jaundice — UKMLA MCQ

Instant feedback + full explanation. One question, done properly.

HardGastroenterologyObstructive JaundiceUKMLAMRCP Part 1

Molecular testing in an adult with advanced non-small-cell lung cancer identifies a MET exon 14 skipping alteration. Performance status permits systemic treatment. Which targeted medicine is recommended within its marketing authorisation by NICE?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Use tepotinib for MET exon 14 skipping advanced NSCLC

The best answer is “Use tepotinib for MET exon 14 skipping advanced NSCLC”. Tepotinib is the NICE-recommended MET inhibitor for advanced NSCLC harbouring a MET exon 14 skipping alteration. Osimertinib targets sensitising EGFR variants, alectinib targets ALK rearrangements, sotorasib targets KRAS G12C and selpercatinib targets RET alterations. The histological and molecular work-up therefore determines treatment; a pancreatic-head-cancer buzzword diagnosis would not test this precision-oncology distinction.

Reference: NICE TA789, Tepotinib for advanced NSCLC with MET alterations: https://www.nice.org.uk/guidance/ta789/chapter/1-Recommendations